More News! 12 Sep 2019 French Biotech to Develop Septic Shock Therapy with €39M Series B The French company Inotrem has raised €39M to fund an immunotherapy for septic shock, an often deadly condition caused by infections in the bloodstream. Led by the Hong Kong investor Morningside Ventures, the Series B round will finance a phase IIb trial of Inotrem’s lead candidate drug nangibotide, expected to start in November this year. […] September 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2019 UK Biotech’s Personalized Immunotherapy gets €110M Series B Boost The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies in humans for the first time. The large Series B round will fund two phase I/IIa clinical trials of Achilles’ preclinical immunotherapy which are expected to start this year: one in non-small cell lung cancer and the other in […] September 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2019 Oncolytic Virus for Liver Cancer Ruled Futile in Phase III A phase III trial testing an oncolytic virus treatment for liver cancer, developed by the French biotech Transgene, has been discontinued after interim analyses concluded that the treatment was unlikely to succeed. Originally expected to finish in 2020, the phase III trial tested the oncolytic virus treatment Pexa-Vec in patients with the liver cancer hepatocellular […] August 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 22 Jul 2019 Turning Shelved Drugs into a New Promise for Immuno-Oncology After working for 12 years at Merck, Catherine Pickering decided to take a risk and create iOnctura, a spin-out company exploring a new application in immuno-oncology for a drug candidate that had been shelved. In the last decade, there has been a massive boom in the development of cancer therapies that use and enhance the […] July 22, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2019 BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […] July 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2019 Belgian Biotech’s €35M Series B to Fund Potential Type 1 Diabetes Cure The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money to fund phase II trials of a peptide-based treatment for type 1 diabetes. The funds will also help the company to launch […] June 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 11 Jun 2019 Gamma Delta T Cells: A New Hope Against Cancer A new wave of therapies based on a unique type of immune cells, called gamma delta T cells, has the potential to treat cancer with stronger responses and fewer side effects. Immunotherapies based on T cells are becoming a huge trend in the treatment of cancer, especially CAR-T cells. These genetically-modified T cells have shown […] June 11, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2019 Highlights from European Biotech at ASCO 2019 European biotech companies gathered in Chicago, USA, to share the latest advances in cancer research at the biggest cancer conference of the year, ASCO 2019. This year’s conference has drawn fewer big blockbuster headlines than other years, but there was plenty to see nonetheless. There were results from many different clinical trials by big pharma […] June 5, 2019 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2019 The Top 20 Women in Leading Biotech Roles in Europe The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way to go to achieve ideal levels of equality, there are more and more women filling leading roles in companies across Europe. Here are 20 women making an impact in the European biotech industry. Diversity comes […] May 21, 2019 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2019 UK Immune Cell Therapy Biotech Founded with €40M Series A Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases, launched today with €40M series A funding. UK life sciences trust Syncona is the lead investor, with a €38.8M stake in the company. Syncona will own a controlling 69% of the business, reflecting their large initial investment. […] May 20, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 13 May 2019 ‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding The Swiss-Italian biotech company Philogen has raised a private round of €62M to fund the phase III development of cancer immunotherapies that deliver immune cell-stimulating molecules directly to the tumor site. The money will push Philogen’s two lead cancer programs, currently in phase III, to the market. The funds will also help to expand the […] May 13, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2019 European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not? We spend a lot of time focusing on specific developments in biotechnology, but sometimes it’s good to take a step back and look at the bigger picture. With this in mind, I asked three experts at our recent Refresh event in Vienna to share what is hot in European biotech right now and what trends […] April 25, 2019 - 11 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email